 John LaMattina
Concepts (173)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 13 | 2021 | 1244 | 4.280 |
Why?
| | Transplantation, Heterologous | 7 | 2022 | 369 | 2.900 |
Why?
| | Thrombocytopenia | 4 | 2022 | 171 | 2.270 |
Why?
| | Graft Survival | 14 | 2022 | 885 | 2.250 |
Why?
| | Kidney Transplantation | 12 | 2018 | 830 | 2.230 |
Why?
| | Living Donors | 7 | 2021 | 298 | 2.210 |
Why?
| | Liver | 6 | 2022 | 1240 | 1.790 |
Why?
| | Hepatectomy | 3 | 2017 | 154 | 1.780 |
Why?
| | Nephrectomy | 4 | 2018 | 297 | 1.450 |
Why?
| | Tissue Scaffolds | 2 | 2017 | 108 | 1.270 |
Why?
| | Swine | 11 | 2022 | 569 | 1.030 |
Why?
| | Deamino Arginine Vasopressin | 1 | 2022 | 12 | 0.960 |
Why?
| | Hepatitis C | 2 | 2015 | 208 | 0.950 |
Why?
| | Pancreas Transplantation | 2 | 2012 | 104 | 0.910 |
Why?
| | Kidney Failure, Chronic | 3 | 2016 | 512 | 0.880 |
Why?
| | Galactosyltransferases | 3 | 2017 | 40 | 0.860 |
Why?
| | Graft Rejection | 8 | 2019 | 1109 | 0.860 |
Why?
| | Kidney Diseases | 3 | 2015 | 421 | 0.860 |
Why?
| | Donor Selection | 2 | 2017 | 66 | 0.800 |
Why?
| | Fluid Therapy | 2 | 2018 | 48 | 0.790 |
Why?
| | Heat Stroke | 1 | 2018 | 5 | 0.780 |
Why?
| | Multiple Organ Failure | 1 | 2018 | 42 | 0.750 |
Why?
| | Immunosuppressive Agents | 3 | 2014 | 1023 | 0.750 |
Why?
| | Lung Transplantation | 2 | 2017 | 237 | 0.750 |
Why?
| | Waiting Lists | 2 | 2020 | 163 | 0.740 |
Why?
| | Neuraminic Acids | 1 | 2017 | 9 | 0.720 |
Why?
| | Animals, Genetically Modified | 5 | 2022 | 188 | 0.720 |
Why?
| | Postoperative Complications | 5 | 2019 | 2265 | 0.680 |
Why?
| | End Stage Liver Disease | 1 | 2017 | 52 | 0.670 |
Why?
| | Bile Ducts | 1 | 2016 | 61 | 0.670 |
Why?
| | Tissue and Organ Harvesting | 1 | 2017 | 80 | 0.670 |
Why?
| | Laparoscopy | 3 | 2018 | 701 | 0.660 |
Why?
| | Tissue and Organ Procurement | 3 | 2020 | 290 | 0.630 |
Why?
| | Hemofiltration | 1 | 2015 | 10 | 0.610 |
Why?
| | Tissue Engineering | 1 | 2017 | 191 | 0.600 |
Why?
| | Retrospective Studies | 12 | 2020 | 7582 | 0.580 |
Why?
| | Intraoperative Care | 1 | 2015 | 94 | 0.570 |
Why?
| | Platelet Glycoprotein GPIb-IX Complex | 1 | 2014 | 5 | 0.560 |
Why?
| | Substance-Related Disorders | 1 | 2018 | 381 | 0.560 |
Why?
| | Immunoglobulin Fab Fragments | 1 | 2014 | 78 | 0.530 |
Why?
| | Hemostasis, Surgical | 1 | 2013 | 30 | 0.520 |
Why?
| | Male | 22 | 2020 | 41802 | 0.510 |
Why?
| | Immunoconjugates | 1 | 2014 | 112 | 0.510 |
Why?
| | Humans | 29 | 2022 | 82932 | 0.510 |
Why?
| | Gene Knockout Techniques | 3 | 2017 | 75 | 0.490 |
Why?
| | Adult | 14 | 2020 | 25931 | 0.470 |
Why?
| | Intensive Care Units | 1 | 2015 | 370 | 0.470 |
Why?
| | Acute Kidney Injury | 1 | 2015 | 274 | 0.460 |
Why?
| | Transplantation, Homologous | 7 | 2017 | 1019 | 0.440 |
Why?
| | Thymus Gland | 5 | 2004 | 224 | 0.420 |
Why?
| | Female | 18 | 2020 | 44644 | 0.410 |
Why?
| | Diabetic Nephropathies | 1 | 2012 | 223 | 0.400 |
Why?
| | Survival Rate | 5 | 2019 | 1918 | 0.390 |
Why?
| | Middle Aged | 14 | 2020 | 25565 | 0.380 |
Why?
| | Animals | 15 | 2022 | 26911 | 0.360 |
Why?
| | Rats, Wistar | 2 | 2017 | 318 | 0.320 |
Why?
| | Extracorporeal Circulation | 2 | 2017 | 25 | 0.320 |
Why?
| | Tissue Donors | 2 | 2020 | 433 | 0.280 |
Why?
| | Biopsy | 2 | 2017 | 1178 | 0.260 |
Why?
| | Clodronic Acid | 1 | 2022 | 7 | 0.240 |
Why?
| | Heme Oxygenase-1 | 1 | 2022 | 18 | 0.240 |
Why?
| | Risk Factors | 6 | 2020 | 5396 | 0.240 |
Why?
| | Perfusion | 1 | 2022 | 171 | 0.230 |
Why?
| | Hematopoiesis | 1 | 2002 | 159 | 0.220 |
Why?
| | Kaplan-Meier Estimate | 2 | 2015 | 900 | 0.220 |
Why?
| | Renin | 1 | 2020 | 76 | 0.210 |
Why?
| | Angiotensin II | 1 | 2020 | 92 | 0.210 |
Why?
| | Vasoconstrictor Agents | 1 | 2020 | 53 | 0.210 |
Why?
| | Reoperation | 3 | 2012 | 626 | 0.210 |
Why?
| | Shock, Septic | 1 | 2020 | 98 | 0.200 |
Why?
| | Papio | 2 | 2014 | 100 | 0.200 |
Why?
| | Time Factors | 5 | 2020 | 5497 | 0.200 |
Why?
| | Renin-Angiotensin System | 1 | 2020 | 133 | 0.200 |
Why?
| | Liver Failure, Acute | 1 | 2018 | 37 | 0.190 |
Why?
| | T-Lymphocytes | 2 | 2003 | 1286 | 0.180 |
Why?
| | Decision Support Techniques | 1 | 2020 | 162 | 0.180 |
Why?
| | Liver Diseases | 1 | 2020 | 224 | 0.180 |
Why?
| | Kupffer Cells | 1 | 2017 | 12 | 0.180 |
Why?
| | Respiratory Insufficiency | 1 | 2019 | 151 | 0.180 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 2019 | 119 | 0.180 |
Why?
| | Hernia, Umbilical | 1 | 2017 | 16 | 0.170 |
Why?
| | Craniocerebral Trauma | 1 | 2017 | 50 | 0.170 |
Why?
| | Cell Tracking | 1 | 2016 | 14 | 0.170 |
Why?
| | Hep G2 Cells | 1 | 2016 | 47 | 0.170 |
Why?
| | Cell Compartmentation | 1 | 2016 | 69 | 0.170 |
Why?
| | Hepatocytes | 1 | 2017 | 125 | 0.170 |
Why?
| | Hospital Mortality | 1 | 2019 | 321 | 0.170 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2016 | 61 | 0.170 |
Why?
| | Fatal Outcome | 1 | 2017 | 309 | 0.170 |
Why?
| | Social Support | 1 | 2018 | 188 | 0.160 |
Why?
| | Follow-Up Studies | 3 | 2019 | 3876 | 0.160 |
Why?
| | Albumins | 1 | 2016 | 120 | 0.160 |
Why?
| | Inflammation | 1 | 2022 | 820 | 0.160 |
Why?
| | Immune Tolerance | 3 | 2004 | 343 | 0.160 |
Why?
| | Heart Arrest | 1 | 2019 | 262 | 0.160 |
Why?
| | Maryland | 1 | 2015 | 28 | 0.150 |
Why?
| | Violence | 1 | 2017 | 116 | 0.150 |
Why?
| | Phosphodiesterase 5 Inhibitors | 1 | 2015 | 10 | 0.150 |
Why?
| | Robotics | 1 | 2018 | 251 | 0.150 |
Why?
| | Cell Lineage | 1 | 2016 | 288 | 0.150 |
Why?
| | Animals, Newborn | 1 | 2016 | 563 | 0.150 |
Why?
| | Risk Assessment | 4 | 2020 | 2278 | 0.140 |
Why?
| | Endothelial Cells | 1 | 2017 | 401 | 0.140 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 1 | 2016 | 128 | 0.140 |
Why?
| | Aged | 3 | 2017 | 18473 | 0.140 |
Why?
| | Comorbidity | 1 | 2018 | 937 | 0.140 |
Why?
| | Immunohistochemistry | 2 | 2017 | 1818 | 0.140 |
Why?
| | von Willebrand Factor | 1 | 2014 | 41 | 0.140 |
Why?
| | Endoscopy | 1 | 2017 | 320 | 0.140 |
Why?
| | Glomerular Filtration Rate | 2 | 2015 | 385 | 0.130 |
Why?
| | Length of Stay | 2 | 2016 | 693 | 0.130 |
Why?
| | Ligation | 1 | 2013 | 58 | 0.130 |
Why?
| | Organ Transplantation | 1 | 2017 | 278 | 0.130 |
Why?
| | Liver Cirrhosis | 1 | 2015 | 255 | 0.130 |
Why?
| | Patient Selection | 1 | 2017 | 692 | 0.130 |
Why?
| | Histocompatibility | 3 | 2017 | 70 | 0.130 |
Why?
| | Swine, Miniature | 5 | 2003 | 49 | 0.120 |
Why?
| | Heart Transplantation | 1 | 2017 | 662 | 0.120 |
Why?
| | Multivariate Analysis | 1 | 2015 | 1011 | 0.120 |
Why?
| | Kidney | 4 | 2015 | 1232 | 0.120 |
Why?
| | Wisconsin | 1 | 2011 | 42 | 0.120 |
Why?
| | Cells, Cultured | 1 | 2017 | 2968 | 0.120 |
Why?
| | C-Peptide | 1 | 2012 | 173 | 0.120 |
Why?
| | Clinical Trials as Topic | 1 | 2017 | 1199 | 0.110 |
Why?
| | Treatment Outcome | 6 | 2020 | 7874 | 0.110 |
Why?
| | DNA | 1 | 2016 | 1300 | 0.110 |
Why?
| | Islets of Langerhans Transplantation | 2 | 2002 | 217 | 0.110 |
Why?
| | Rats | 1 | 2017 | 4348 | 0.110 |
Why?
| | Cell Proliferation | 1 | 2016 | 1611 | 0.110 |
Why?
| | Reproducibility of Results | 1 | 2016 | 2664 | 0.100 |
Why?
| | Proportional Hazards Models | 1 | 2011 | 870 | 0.090 |
Why?
| | Islets of Langerhans | 2 | 2002 | 539 | 0.090 |
Why?
| | Chronic Disease | 1 | 2011 | 964 | 0.090 |
Why?
| | Disease Progression | 1 | 2011 | 1468 | 0.080 |
Why?
| | Incidence | 1 | 2011 | 1637 | 0.080 |
Why?
| | Young Adult | 1 | 2018 | 5954 | 0.080 |
Why?
| | Pancreatectomy | 2 | 2002 | 155 | 0.070 |
Why?
| | Prognosis | 1 | 2011 | 3694 | 0.060 |
Why?
| | Prospective Studies | 1 | 2011 | 4063 | 0.060 |
Why?
| | Transplantation Tolerance | 1 | 2003 | 116 | 0.060 |
Why?
| | Severity of Illness Index | 2 | 2020 | 1777 | 0.060 |
Why?
| | Tacrolimus | 1 | 2001 | 384 | 0.050 |
Why?
| | Blood Glucose | 1 | 2002 | 897 | 0.040 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2002 | 543 | 0.040 |
Why?
| | Databases, Factual | 1 | 2020 | 787 | 0.040 |
Why?
| | Pain, Postoperative | 1 | 2018 | 236 | 0.040 |
Why?
| | Wound Healing | 1 | 2018 | 350 | 0.040 |
Why?
| | Patient Safety | 1 | 2018 | 212 | 0.040 |
Why?
| | Blood Loss, Surgical | 1 | 2016 | 106 | 0.040 |
Why?
| | Injections, Intravenous | 1 | 2015 | 269 | 0.040 |
Why?
| | Blood Transfusion | 1 | 2016 | 152 | 0.040 |
Why?
| | Predictive Value of Tests | 1 | 2020 | 1753 | 0.040 |
Why?
| | Drug Monitoring | 1 | 2015 | 120 | 0.040 |
Why?
| | Transplantation, Heterotopic | 2 | 2003 | 46 | 0.030 |
Why?
| | Patient Readmission | 1 | 2016 | 276 | 0.030 |
Why?
| | Patient Satisfaction | 1 | 2016 | 441 | 0.030 |
Why?
| | United States | 1 | 2020 | 6273 | 0.020 |
Why?
| | Insulin | 2 | 2002 | 1169 | 0.020 |
Why?
| | Immunotoxins | 1 | 2003 | 13 | 0.020 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 2003 | 97 | 0.020 |
Why?
| | Major Histocompatibility Complex | 1 | 2003 | 92 | 0.020 |
Why?
| | Surgically-Created Structures | 1 | 2002 | 4 | 0.020 |
Why?
| | Omentum | 1 | 2003 | 70 | 0.020 |
Why?
| | Cyclosporine | 1 | 2003 | 251 | 0.020 |
Why?
| | Creatinine | 1 | 2003 | 346 | 0.020 |
Why?
| | Postoperative Period | 1 | 2002 | 314 | 0.010 |
Why?
| | Hyperglycemia | 1 | 2002 | 183 | 0.010 |
Why?
| | Antibodies | 1 | 2003 | 370 | 0.010 |
Why?
| | Histocompatibility Testing | 1 | 2001 | 157 | 0.010 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2001 | 171 | 0.010 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2001 | 204 | 0.010 |
Why?
| | Drug Administration Schedule | 1 | 2001 | 973 | 0.010 |
Why?
| | Haplotypes | 1 | 2001 | 641 | 0.010 |
Why?
|
|
LaMattina's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|